KCA
Search
- Page Path
- HOME > Search
Original Articles
- Sarcoma
- Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single-Center Study
- Xin Liu, Chengcheng Gong, Jieyun Zhang, Wanjing Feng, Yanjing Guo, Youzhou Sang, Chunmeng Wang, Yong Chen, Jian Wang, Lin Yu, Xiaowei Zhang, Zhiguo Luo
- Cancer Res Treat. 2023;55(3):1001-1010. Published online March 3, 2023
- DOI: https://doi.org/10.4143/crt.2022.894
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal malignancy that occurs primarily in children and adolescents. The clinical and pathological features of IMT in adult patients are not well understood.
Materials and Methods
We retrospectively searched for records of adult patients with IMT at Fudan University Shanghai Cancer Center from 2006 to 2021. Clinicopathological data, treatments, and outcomes were collected and analyzed.
Results
Thirty adult patients with IMT, mostly women (60.0%), were included. The median age of the patients was 38 (21-77). The most common primary site was abdominopelvic region (53.3%), followed by lungs (20.0%). Seven patients had an abdominal epithelioid inflammatory myofibroblast sarcoma (EIMS). The positivity rate of anaplastic lymphoma kinase (ALK) was 81.5% (22/27). Sixteen patients with advanced ALK-positive disease received crizotinib, with an objective response rate (ORR) of 81.3% and a disease control rate of 87.5%. The median progression-free survival was 20.8 months. EIMS was associated with more aggressive behavior; however, the prognosis was similar to that of non-EIMS patients after treatment with an ALK inhibitor. At a median follow-up time of 30 months (95% confidence interval [CI], 13.6 to 46.4), the 5-year overall survival was 77% (95% CI, 66 to 88) in all patients.
Conclusion
Adult IMTs appeared more aggressive, with a higher incidence of recurrence and metastases, and patients with EIMS had more aggressive cases. Treatment with ALK inhibitors resulted in a high ORR and a durable response, which suggested that ALK inhibitors could be used as a first-line treatment option in adult patients with ALK-positive advanced IMT. -
Citations
Citations to this article as recorded by
- Clinicopathological Characteristics of Inflammatory Myofibroblastic Tumor: A Single Center Retrospective Cohort Study
Xiaoyan Si, Shafei Wu, Ruie Feng, Mengzhao Wang, Hanping Wang, Xiaotong Zhang, Li Zhang, Kaifeng Xu
Thoracic Cancer.2025;[Epub] CrossRef - Case report: Intra-abdominal inflammatory myofibroblastic tumor with mucinous features: a case of rapid recurrence and dissemination post-surgery
Xingchen Li, Jie Li, Chunxiao Liang, Qing Zou
Frontiers in Oncology.2025;[Epub] CrossRef - Clinical diagnosis and treatment of abdominal inflammatory myofibroblastic tumors
Qiang Zhang, Zhi-wei Zhang, Jing Fan, Zhuo-Ma Ji, Chun-Yan Wang, Feng Liu
Discover Oncology.2025;[Epub] CrossRef - Therapeutic strategy and prognostic analysis of inflammatory myofibroblastic tumor in the head and neck: a retrospective study
Feng Liu, Yanchao Qin, Zhiwei Zhang, Mengru Li, Bowei Feng, Wei Ding, Shubin Dong
PeerJ.2025; 13: e19315. CrossRef - Inflammatory myofibroblastic tumor of the adrenal gland: A case report
Jiyao Yang, Hongjin Shi, Haifeng Wang, Yidao Liu
Urology Case Reports.2024; 55: 102763. CrossRef - Ibero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical Recommendations
Francisco Cristóbal Muñoz-Casares, Javier Martín-Broto, Pedro Cascales-Campos, Juan Torres-Melero, Irene López-Rojo, José Gómez-Barbadillo, Luis González-Bayón, Ana Sebio, César Serrano, Sara Carvalhal, Joaquim Abreu de Souza, Alexandre Souza, Guillermo F
Cancers.2024; 16(15): 2646. CrossRef - Thoracic epithelioid inflammatory myofibroblastic sarcoma: a rare and aggressive disease with case report and literature review
Linke Yang, Pei Li, Runze Liu, Baomin Feng, Huiqing Mao, Xiaoyong Tang, Guangjian Yang
Discover Oncology.2024;[Epub] CrossRef - Metastasized inflammatory myofibroblastic tumor of uterine origin
Thomas Bartl, Michael Deavers, Ryan Blair Kieser, Pedro T Ramirez
International Journal of Gynecological Cancer.2024; 34(10): 1643. CrossRef - Epithelioid inflammatory myofibroblastic sarcoma with exceptionally long response to lorlatinib—a case report
Rafał Becht, Kajetan Kiełbowski, Justyna Żychowska, Wojciech Poncyljusz, Aleksandra Łanocha, Katarzyna Kozak, Ewa Gabrysz-Trybek, Paweł Domagała
Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef - Rare giant epithelioid inflammatory myofibroblastic sarcoma of the abdominal cavity in a child: a case report and review of the literature
Jinzhou Li, Haixing Su, Sheng Zhang, Xianyun Chen, Chongzhi Hou, Tao Cheng
Frontiers in Oncology.2024;[Epub] CrossRef - Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment
PAULINA CHMIEL, ALEKSANDRA SłOWIKOWSKA, ŁUKASZ BANASZEK, ANNA SZUMERA-CIEćKIEWICZ, BARTłOMIEJ SZOSTAKOWSKI, MATEUSZ J. SPAłEK, TOMASZ ŚWITAJ, PIOTR RUTKOWSKI, ANNA M. CZARNECKA
Oncology Research.2024; 32(7): 1141. CrossRef
- Clinicopathological Characteristics of Inflammatory Myofibroblastic Tumor: A Single Center Retrospective Cohort Study
- 3,994 View
- 144 Download
- 9 Web of Science
- 11 Crossref
- Stomach Carcinoma in the Young Adults - Analysis of 111 Cases , and Review from Literatures -
- Dong Soo Suk
- J Korean Cancer Assoc. 1990;22(1):202-208.
-
Abstract
PDF
- There are lll cases under 40 years old out of 584 stomach carcinoma from Seoul and Pusan Paik hospitals, Korea. It is 19. 0% of the total stomach carcinoma, and male-female ratio is 1 2: l. Under 35 years, it is 10.0%(62 cases), and male-female ratio is 0.9: l. Undifferentiated carcinoma is the predominant type, 76.7%, and differentiated type 23.3%. Proximal parts of stomach (body, fundus, cardia) are affected more, 46.8%, and antrum 38.5%, and body with antrum 14.7%. The present data (10.6%) of the incidence under 35 years old is notably higher than that of Japan (1.7-2.8%) and America (0.49~2.2%). These data of the incidence appear proportionally high with the degree of risk factors of these three countries. There are more undifferentiated or diffusely infiltrating type in the young adults, and the incidence of this type is stable without affected much by the environmental factor. Only differentiated or intestinal type of stomach cancer is variable with the enviromentai risk factor. These facts suggest that enviromental factor is mostly responsible for the development of intestinal type, and hereditary factor for the diffuse type. Based upon these presumptions, it is easily understandable ta find an each different male-female ratio in older and younger age groups (2: 1, 1: 1, respectively). These principal findings can be expected to exist in other human cancers which are developed by known or suspected carcinogenic agents. Leukemia and nasopharyngeal carcinoma are good examples. For, it is speculated that in young age group, hereditary factor is the cause, and in older age group, environmental factor is the cause in the above cancers.
- 2,713 View
- 24 Download
First
Prev
